Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC with Gemcitabine for resected pancreatic cancer
NCT04969731Phase 3Recruiting
- Sponsor
- GC Cell
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of immuncell-lc in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by GC Cell. Primary endpoint: Recurrence free survival at 36 months. Started Sep 2021; status: recruiting.
02
Drugs
immuncell-lc
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04969731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969731.